Alternatives to Gritstone

All-in-One LIMS, ELN, QMS, and DMS Platform Xybion LIMS is an all-inclusive Digital Laboratory system including LIMS, ELN, QMS, and DMS that creates optimized workflows for the unique business needs of all regulated laboratories including research, diagnostics, quality control, stability studies, and more. Xybion LIMS instills consistency, improves data quality, and supports regulatory compliance with a complete laboratory management solution that connects with your operating systems with powerful laboratory information management and analytics.

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

NoviSight 3D cell analysis software enhances your research by delivering statistical insights for spheroids and various 3D structures in microplate experiments. This software allows for the quantification of cellular activity in three dimensions, facilitating the capture of infrequent cellular occurrences, providing precise cell counts, and boosting detection sensitivity. Featuring an intuitive user interface, NoviSight equips you with essential tools for recognition, analysis, and statistical evaluation. Its True 3D technology simplifies the assessment of sample morphology, allowing for the measurement of various parameters such as volume and sphericity of spheroids or cell nuclei. Additionally, it enables the examination of physiologically relevant 3D cell models, thereby accelerating your research processes. The software is capable of analyzing objects of interest to yield morphology and spatiotemporal parameters within a 3D context. Furthermore, it can detect a range of entities, from entire structures to subcellular components, and assess changes occurring in spheroids, ultimately contributing to a deeper understanding of cellular dynamics. This comprehensive analysis ultimately supports researchers in their quest to uncover critical biological insights.

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

The process of launching a new medication into the market is not only lengthy and costly but also heavily regulated, often extending beyond a decade. The overall success of this endeavor significantly hinges on obtaining precise analytical data early on, which is crucial for making informed decisions during the initial stages of development and for reducing the risk of failures later on. Modern drug development predominantly follows a logical framework, beginning with the identification of a biological target that serves as the focal point for research. This initial step necessitates a thorough comprehension of the characteristics of potential candidates to swiftly and reliably pinpoint the most viable options. After establishing this biological target, the next major hurdle is to discover the most promising lead molecules, which involves identifying potential drug candidates, whether they be small organic compounds or biologic structures that exhibit therapeutic promise. Moreover, the entire process requires interdisciplinary collaboration and innovation, underscoring the complexity of transforming a scientific idea into a viable medication.

Our innovative AI platform revolutionizes the field of drug discovery, enabling us to develop superior medications at an accelerated pace. With a diverse portfolio of discovery assets—both fully owned and collaboratively developed—and the support of renowned investors, we are making significant strides in the industry. Atomwise has crafted a machine-learning discovery engine that leverages the capabilities of convolutional neural networks alongside extensive chemical libraries to identify novel small-molecule drugs. The key to transforming drug discovery through AI lies in the expertise and commitment of our team. We are focused on creating the most effective AI tools to enhance small molecule drug discovery, striving to address the toughest and seemingly insurmountable targets while streamlining the entire process for drug developers. By maximizing computational efficiency, we can screen trillions of compounds virtually, significantly boosting the chances of success. Our models have demonstrated remarkable accuracy, effectively mitigating the issue of false positives and paving the way for groundbreaking advancements in medicine. Ultimately, our mission is to empower researchers with the technology they need to drive innovation and achieve transformative results in drug discovery.

The biopharmaceutical sector today is characterized by its intricate nature, driven by increasing demands for enhanced specificity and safety, the emergence of new treatment modalities, and a deeper understanding of complex disease mechanisms. To navigate this intricate landscape, a thorough grasp of therapeutic behavior is essential. Modeling and simulation techniques serve as a powerful method to investigate biological and physicochemical phenomena at the atomic scale, which can inform experimental work and expedite both discovery and development timelines. BIOVIA Discovery Studio consolidates over three decades of rigorously validated research alongside cutting-edge in silico methodologies, including molecular mechanics, free energy assessments, and the development of biotherapeutics, all within a unified platform. This comprehensive toolkit empowers researchers to delve into the subtleties of protein chemistry, facilitating the discovery and optimization of both small and large molecule therapeutics from the identification of targets through to lead optimization, thereby enhancing the overall efficiency of the drug development process. In an era where precision medicine is increasingly pivotal, such tools are indispensable for advancing therapeutic innovation.

BIOiSIMTM represents a groundbreaking 'virtual drug development engine' that delivers exceptional advantages to the pharmaceutical sector by efficiently identifying drug compounds with promising potential for treating or curing targeted diseases. Our suite of translational solutions is tailored to meet the specific needs of your pre-clinical and clinical initiatives. Central to these offerings is our validated and reliable BIOiSIMTM platform, which caters to small molecules, large molecules, and viruses. Our sophisticated models leverage data from thousands of compounds spanning seven different species, resulting in a level of robustness that is uncommon in the industry. With a strong emphasis on human outcomes, the platform features a translatability engine that effectively converts insights across various species. Notably, the BIOiSIMTM platform can be utilized prior to the commencement of preclinical animal trials, facilitating earlier insights and reducing the costs associated with outsourced testing. This innovative approach not only enhances efficiency but also accelerates the overall drug development process, ultimately benefiting the quest for effective treatments.

AutoDock comprises a collection of automated docking tools aimed at forecasting the binding interactions of small molecules, like substrates or potential pharmaceuticals, with receptors that have a defined three-dimensional structure. Over time, the suite has undergone various modifications and enhancements to incorporate additional features, resulting in the development of several engines. The current versions of AutoDock include two primary iterations: AutoDock 4 and AutoDock Vina. Recently, an advanced version known as AutoDock-GPU was introduced, which accelerates the docking process of AutoDock 4 and achieves speeds that are hundreds of times greater than its original single-CPU counterpart. AutoDock 4 is fundamentally made up of two key applications: autodock, which facilitates the docking of ligands to a grid representation of the target protein, and autogrid, which computes these grids in advance. Besides their application in docking, the atomic affinity grids generated can also be visualized, providing valuable insights that can assist organic synthetic chemists in creating more effective binders for their projects. This capability helps bridge the gap between computational predictions and practical applications in drug design.

Discngine Assay serves as a comprehensive laboratory informatics platform that unifies all stages of plate-based assays into a streamlined, compliant, and effective workflow, proving to be a vital resource for screening research laboratories. This platform empowers researchers to optimize their entire High Throughput Screening process, encompassing everything from managing samples and analyzing assay data to data storage and qualifying liquid handling instruments. With its user-friendly interface and powerful API, Discngine Assay integrates effortlessly with laboratory equipment and the existing IT infrastructure, facilitating effective data collection and processing. Tailored to expedite the discovery of new molecules, it meets the requirements of the pharmaceutical, biotech, and contract research organization sectors, thereby promoting collaboration and fostering innovation within life sciences research. Furthermore, its ability to adapt to various laboratory environments makes it a versatile solution for evolving research demands.

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

The microbiome plays a significant role in various diseases and health issues. Discover how Kaleido is pioneering a unique method to transform the potential of the microbiome into effective patient solutions. Comprising over 30 trillion microbes, the human microbiome includes a diverse array of organisms such as bacteria, viruses, archaea, and fungi that inhabit both the exterior and interior of the human body. In recent years, there has been a remarkable surge in research focusing on the microbiome's influence on human health, linking it to conditions such as cardiovascular disease, cancer, diabetes, Parkinson’s disease, and allergies. This intricate microbial community has been likened to a "newly discovered organ," highlighting its significance. Just as many human organs command substantial investments for therapies that modify physiology, the microbiome represents a largely unexplored territory in the realm of healthcare. Addressing this frontier could unlock new therapeutic avenues and enhance overall health outcomes.

Site-Identification by Ligand Competitive Saturation (SILCS) produces three-dimensional maps, known as FragMaps, that illustrate how different chemical functional groups interact with a specific target molecule. By revealing the complexities of molecular dynamics, SILCS offers tools that enhance the optimization of ligand scaffolds through both qualitative and quantitative insights into binding pockets, thereby streamlining the drug design process. This approach employs a range of small molecule probes, each featuring diverse functional groups, alongside explicit solvent modeling and accommodating the flexibility of the target molecule to effectively map protein targets. Furthermore, the technique allows researchers to visualize advantageous interactions with the target macromolecule. With these insights, scientists can strategically design improved ligands with functional groups situated in optimal positions for enhanced efficacy. The innovative nature of SILCS represents a significant advancement in the field of medicinal chemistry.

When utilizing LC-MS/MS for either research purposes or routine tasks, you anticipate obtaining results that are not only swift but also precise and definitive. The SCIEX software suite enhances the functionality of your high-performance LC-MS/MS system by providing tailored workflow and application modules to complement your operating system. Consequently, your mass spectrometer operates with an optimized software mix that aligns with your specific requirements. These components represent the fundamental engines behind SCIEX's nominal mass and accurate mass LC-MS/MS systems, facilitating quick and dependable data collection, processing, and reporting, all while ensuring compliance readiness. By integrating high performance with user-friendly features and additional modules, you can refine both quantitative and qualitative workflows. Furthermore, the implementation of application-specific software modules allows for a more rapid transformation of your data into definitive results, streamlining your research process significantly. This combination of efficiency and adaptability in software applications is crucial for advancing your analytical capabilities.

3decision® serves as an innovative cloud-based repository for protein structures, focusing on efficient structural data management and sophisticated analytics to expedite the discovery of small molecules and biologics through structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from public databases such as RCSB PDB and AlphaFoldDB, along with proprietary datasets, while supporting various formats like PDBx/mmCIF and ModelCIF. This approach guarantees straightforward access to a range of structural data, including X-Ray, NMR, cryo-EM, and modeled structures, which promotes teamwork and enhances scientific research endeavors. In addition to mere storage, 3decision® enriches its database entries with significant metadata and sequence details, covering aspects such as protein-ligand interactions, antibody annotations, and binding site characteristics. Its advanced analytical tools facilitate the identification of potential druggable sites, evaluation of off-target effects, and comparisons of binding sites, effectively converting extensive structural data into practical insights. Moreover, the cloud-based nature of this platform encourages seamless collaboration among research teams, making it an essential tool for advancing drug discovery initiatives.

Aurora utilizes principles of quantum mechanics, thermodynamics, and a sophisticated continuous water model to assess the solvation effects when calculating the binding affinities of ligands. This methodology stands in stark contrast to traditional scoring functions typically employed in predicting binding affinities. By integrating entropy and aqueous electrostatic factors directly into their calculations, Aurora's algorithms yield significantly more precise and reliable estimates of binding free energies. The interaction between a ligand and a protein is fundamentally determined by the binding free energy, which is a thermodynamic measure linked directly to the experimentally observable inhibition constant (IC50). This free energy (F) is influenced by various factors, including electrostatic interactions, quantum effects, solvation dynamics, and the statistical behaviors of the molecules involved. Two primary components contribute to the non-additive nature of F: first, the combined effects of electrostatic and solvation energy, and second, the entropy involved in the system. Understanding these contributions allows for a deeper insight into the molecular interactions at play.

Harness the capabilities of artificial intelligence to accelerate the transition from laboratory research and experimental findings to the introduction of transformative therapies. Achieve a remarkable increase in research efficiency, potentially improving productivity by as much as 90% by cutting down your literature review time from several months to mere minutes. Eliminate distractions and enhance your search capabilities with a precise and accurate tool that simplifies the navigation of the expanding landscape of scientific publications. This approach not only saves time but also minimizes bias and enhances the likelihood of discovering groundbreaking insights. Delve deeply into the intricacies of disease biology and engage in sophisticated target identification. Causaly's advanced knowledge graph integrates data from countless publications, enabling thorough and objective scientific investigations. Effortlessly explore the intricate biological cause-and-effect dynamics without requiring extensive expertise. Access a comprehensive array of scientific documents and reveal previously overlooked connections. Causaly’s robust AI system processes millions of biomedical articles, facilitating improved decision-making and enhancing research outcomes, ultimately leading to a more informed and innovative scientific community. By utilizing such tools, researchers can significantly transform their methodologies and enhance their contributions to medicine.

Genedata Imagence® provides a platform for training deep neural networks that classify cellular phenotypes in high-content screening (HCS) images, ensuring that the results are both unbiased and of superior quality. By automating the analysis process, it enables assay biologists to harness the capabilities of deep learning algorithms effectively. With Genedata Imagence, biologists can analyze HCS imaging data in real-time using advanced deep learning methods, all without requiring extensive knowledge of the underlying algorithms. This eliminates the complexity often associated with data analysis, as the user-friendly interface of Genedata Imagence facilitates quality control and data exploration throughout the entire workflow. As a result, researchers can focus on deriving insights rather than getting lost in intricate coding.

Revolutionize the fields of drug discovery and materials research through cutting-edge molecular modeling techniques. Our computational platform, grounded in physics, combines unique solutions for predictive modeling, data analysis, and collaboration, facilitating swift navigation of chemical space. This innovative platform is employed by leading industries globally, serving both drug discovery initiatives and materials science applications across various sectors including aerospace, energy, semiconductors, and electronic displays. It drives our internal drug discovery projects, overseeing processes from target identification through hit discovery and lead optimization. Additionally, it enhances our collaborative research efforts aimed at creating groundbreaking medicines to address significant public health challenges. With a dedicated team of over 150 Ph.D. scientists, we commit substantial resources to research and development. Our contributions to the scientific community include more than 400 peer-reviewed publications that validate the efficacy of our physics-based methodologies, and we remain at the forefront of advancing computational modeling techniques. We are steadfast in our mission to innovate and expand the possibilities within our field.

BioNeMo is a cloud-based service for drug discovery that utilizes artificial intelligence, leveraging NVIDIA NeMo Megatron to facilitate the training and deployment of large biomolecular transformer models at an extensive computing scale. This platform offers pre-trained large language models (LLMs) along with inherent compatibility for various file formats related to proteins, DNA, RNA, and chemistry, and features data loaders for SMILES to represent molecular structures and FASTA for amino acid and nucleotide sequences. Users will also have the option to download the BioNeMo framework to run it on their own systems. Among its offerings are ESM-1, derived from Meta AI’s cutting-edge ESM-1b, and ProtT5, both of which are transformer models designed for protein language applications that aid in generating learned embeddings for tasks such as predicting protein structure and properties. Additionally, the service will include OpenFold, an advanced deep learning model dedicated to predicting the 3D structures of novel protein sequences, further enhancing its capabilities in the realm of biomolecular research. This comprehensive suite of tools positions BioNeMo as a valuable resource for researchers in the field of drug discovery.

Makya stands out as the pioneering user-centric SaaS platform dedicated to AI-enhanced de novo drug design, particularly emphasizing Multi-Parametric Optimization (MPO). This innovative tool empowers users to create novel and easily synthesize compounds based on a multi-objective framework, achieving unprecedented levels of speed, efficiency, and variety. Makya incorporates a range of generative algorithms tailored to various stages of drug development, from hit discovery to lead optimization; it includes a fine-tuning generator for pinpointing ideal solutions within your specified chemical landscape, a novelty generator designed to explore fresh concepts for re-scaffolding and hit discovery, and a forward generator to create a targeted library of compounds that can be readily synthesized from commercially available starting materials. The recently introduced Makya 3D module significantly improves both the user interface and the scientific capabilities of the platform. With a comprehensive array of 3D modeling functionalities available for both ligand-based and structure-based approaches, Makya 3D allows for the calculation of 3D scores, which can be seamlessly utilized to guide compound generation within the platform. This integration not only enhances the design process but also offers researchers deeper insights into their molecular designs.

We are a biotechnology firm in the clinical stage, dedicated to unraveling biological complexities through the integration of cutting-edge innovations spanning biology, chemistry, automation, machine learning, and engineering, all aimed at revolutionizing drug discovery. Our approach allows for enhanced precision in biological manipulation with advanced techniques like CRISPR genome editing and synthetic biology. We also achieve reliable automation for intricate laboratory processes at an unprecedented scale through the use of sophisticated robotics. By employing neural network architectures, we conduct iterative analyses and draw insights from extensive, intricate datasets generated in-house. Furthermore, we are boosting the adaptability of high-performance computing capabilities through cloud-based solutions. Our initiative harnesses new technologies to foster continuous learning cycles around our datasets, establishing us as a next-generation biopharmaceutical enterprise. This is achieved through a harmonious integration of hardware, software, and data, all dedicated to the industrialization of drug discovery. We are transforming the conventional drug discovery pipeline and boast one of the most extensive, diverse, and in-depth pipelines among technology-driven drug discovery companies. Ultimately, our mission is to enhance the efficiency and effectiveness of drug development, paving the way for breakthrough therapies.

Since its inception in 1985, ChemDraw® solutions have delivered exceptional features and integrations that allow users to swiftly convert their concepts and sketches into impressive publications. ChemOffice+ Cloud serves as a comprehensive suite for chemistry communication, transforming chemical illustrations into valuable knowledge by streamlining the management, reporting, and presentation of chemistry research. This powerful suite is specifically designed to enhance and expedite communication within the field of chemistry. Building upon the foundation of ChemDraw Professional, ChemOffice+ Cloud offers a wide range of advanced tools that support scientific inquiry and collaboration. The once tedious process of drafting reports for chemical research is now significantly more efficient thanks to ChemOffice+ Cloud. With its robust capabilities for searching, reusing, selecting, and organizing chemical structures and data, chemists can effortlessly create polished PowerPoint presentations and manuscripts, making their work more accessible and impactful. This transformation not only saves time but also elevates the overall quality of research dissemination in the scientific community.

To expedite innovative breakthroughs and swiftly bring products to market, research and development alongside manufacturing facilities must adapt and modify their processes in real time. Data management should never become a hindrance in this dynamic landscape. The Thermo Scientific™ Nautilus LIMS™ for Dynamic Discovery and R&D Environments, co-developed with clients operating in rapid R&D contexts, offers a highly adaptable and user-friendly system that enhances workflow efficiency, increases throughput, and ensures data accuracy while streamlining administrative tasks, sample tracking, and adherence to regulatory standards. Its automated management of intricate boards and specialized graphics tools simplifies data oversight, allowing even less experienced users to easily identify and monitor processes. Clients are empowered to design workflows, track the life cycles of samples, and automate interactions across various platforms while seamlessly incorporating regulated protocols that conform to good laboratory practices and the 21 CFR Part 11 regulations. This innovative approach not only fosters a more efficient research environment but also encourages collaboration and creativity among teams.

Business intelligence in the global biopharmaceutical sector focuses on drug patent dynamics and the entry of generics. It is essential to forecast future budget needs and proactively seek out generic alternatives. Analyzing the achievements of past patent challengers provides insights into the competitive landscape and informs research directions. This analysis plays a crucial role in guiding portfolio management strategies for upcoming drug development projects. Additionally, anticipating the expiration of patents on branded drugs, pinpointing potential generic suppliers, and managing branded drug inventory effectively are vital. Furthermore, acquiring detailed formulation and manufacturing data helps in identifying key formulators, repackagers, and relabelers to streamline operations and enhance market positioning. Understanding these elements can significantly bolster strategic decision-making in the biopharmaceutical industry.

We have established ourselves as frontrunners in the fields of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology, a status achieved through the achievements our clients have experienced while partnering with us. Leveraging over two decades of expertise, our skilled team excels at transforming complex scientific concepts into accessible software solutions, while also offering specialized consulting services that bolster drug discovery, clinical development research, and regulatory submission processes. Our dedication to client success drives our continuous improvement and innovation in these critical areas.

FCS Express™ simplifies the transition from raw data to visually appealing, presentation-ready outcomes more efficiently than any other flow cytometry software available. If you've experienced the hassle of transferring tables of data into another application merely for the sake of creating a more digestible visual representation, you're not alone. Managing your data through multiple programs, such as your flow cytometry software in conjunction with Microsoft Excel™ or GraphPad Prism™, can be frustrating when you wish everything were consolidated in one tool. The learning curve associated with flow cytometry software should not hinder your ability to derive meaningful insights from your data. FCS Express is crafted to resemble and function like familiar Microsoft Office™ applications, allowing you to leverage your existing skills and become proficient with the software right from the start. This seamless integration not only saves time but also enhances productivity, enabling users to focus on analysis rather than technicalities.

Clara provides specialized tools and pre-trained AI models that are driving significant advancements across various sectors, such as healthcare technologies, medical imaging, pharmaceutical development, and genomic research. Delve into the comprehensive process of developing and implementing medical devices through the Holoscan platform. Create containerized AI applications using the Holoscan SDK in conjunction with MONAI, and enhance deployment efficiency in next-gen AI devices utilizing the NVIDIA IGX developer kits. Moreover, the NVIDIA Holoscan SDK is equipped with acceleration libraries tailored for healthcare, alongside pre-trained AI models and sample applications designed for computational medical devices. This combination of resources fosters innovation and efficiency, positioning developers to tackle complex challenges in the medical field.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.

BC platforms harnesses cutting-edge scientific advancements, innovative technological capabilities, and strategic alliances to transform drug discovery and tailor healthcare solutions. Our platform is modular and highly adaptable, designed for integrating healthcare data effectively. With an open analytics framework, we seamlessly merge the most recent innovative methods and technology advancements into a single, cohesive platform. We prioritize security, holding ISO 27001 certification alongside compliance with GDPR and HIPAA regulations. Our comprehensive product suite empowers a contemporary healthcare system to fully adopt personalized medicine approaches. Our scalable deployment options support everything from initial setups to expansive healthcare operations. By offering a unique end-to-end toolbox, we facilitate the expedited application of research findings in clinical settings. Moreover, we strive to minimize your risks, enhance the value of your pipeline, and advance your enterprise data strategy by overcoming data access challenges and enabling swift insights. In doing so, we aim to foster a health ecosystem that is both responsive and forward-thinking.

Harnessing RNA sequencing (RNA-seq) data alongside Artificial Intelligence presents both a crucial necessity and a significant opportunity for creating therapies aimed at correcting splicing errors. By leveraging machine learning, we can uncover novel splicing errors and swiftly formulate therapeutic compounds to address them. Our AI platform, SpliceCore, is specifically designed for discovering RNA therapeutics. This cutting-edge technology focuses on analyzing RNA sequencing data with unparalleled efficiency. It can swiftly identify, evaluate, and validate potential drug targets, outpacing traditional methodologies. Central to SpliceCore is our unique repository containing over 5 million potential RNA splicing errors, making it the largest of its kind globally and instrumental for testing any RNA sequencing dataset submitted for analysis. The integration of scalable cloud computing allows us to handle vast quantities of RNA sequencing data in a way that is not only efficient but also cost-effective, significantly speeding up the pace of therapeutic advancements. This innovative approach promises to revolutionize the landscape of RNA therapeutics.

Discover valuable insights within your data by utilizing the Cortellis™ suite of life science intelligence tools, enabling you to make more informed decisions throughout the entire R&D process. We have alleviated the burden of gathering, integrating, and analyzing data, allowing you to concentrate on the essential choices necessary for expediting your products' market entry. With a unique combination of extensive, high-quality data, fortified by profound domain knowledge, industry insight, and therapeutic expertise, Cortellis reveals crucial insights that facilitate data-driven decisions, ultimately speeding up innovation. Access tailored, actionable responses to your specific inquiries throughout the R&D lifecycle, drawing from the most comprehensive and in-depth intelligence sources available. By incorporating Cortellis into your daily routine, you can significantly enhance the pace of innovation and streamline your workflow. This makes Cortellis not just a tool, but a vital partner in your path to success.

Brainlab's Elements Spine Stereotactic Radiosurgery (SRS) represents a cutting-edge software solution aimed at refining the management of spinal metastases. This innovative workflow features automation at each phase, encompassing anatomical mapping, curvature adjustments, and target identification, which guarantees precision and uniformity down to submillimetric levels. A distinctive algorithm addresses variations in spinal curvature, thereby improving the accuracy of image fusion. The software employs automatic segmentation of spinal anatomy through a patented synthetic tissue model that effectively identifies and labels different spine levels for accurate dose calculations. Tools for outlining spinal tumors are included for Gross Tumor Volume (GTV) contouring, along with automatic suggestions for the Clinical Target Volume (CTV) and a cropped spinal canal object in alignment with International Spine Consortium Guidelines. Furthermore, the integration of AI-driven contouring solutions allows for the swift and dependable delineation of over 200 structures, including lymph nodes. This advancement not only streamlines the treatment process but also enhances overall patient outcomes in spinal cancer management.

Tempus AI, a prominent health technology firm based in Chicago, Illinois, is dedicated to transforming patient care through advanced artificial intelligence and precision medicine. By utilizing data and AI, the company strives to create personalized treatment plans across a range of medical specialties, such as oncology, cardiology, radiology, and mental health. Their all-encompassing platform combines genomic sequencing, clinical data, and AI-powered analytics, equipping healthcare providers and researchers with actionable insights. Tempus offers a holistic understanding of patients via various testing methods, including tissue and liquid biopsies, DNA and RNA sequencing, somatic and germline tests, as well as tumor-normal matched profiling and minimal residual disease monitoring options. Additionally, they provide a swift and dependable platform for ordering tests, gaining patient insights, and seamlessly integrating AI-driven technologies into practice. Furthermore, Tempus features an innovative generative AI-enabled clinical assistant that places patient insights readily at your fingertips, enhancing the overall efficiency of healthcare delivery. This commitment to leveraging cutting-edge technology exemplifies Tempus AI's mission to improve health outcomes and advance medical research.

Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.

Founded in 2000, VeraChem LLC aims to enhance the field of computer-aided drug discovery and molecular design by creating advanced computational chemistry techniques that merge innovative basic science with practical applications in research. A key aspect of the company's strategy for product development lies in delivering efficient, high-performance software solutions along with extensive user support. Among the current capabilities of VeraChem's software are predictions for protein-ligand and host-guest binding affinities, rapid and precise calculations of partial atomic charges for drug-like molecules, and the computation of energies and forces utilizing widely-used empirical force fields. Additionally, the software features automatic generation of alternate resonance forms for drug-like compounds, a robust conformational search enabled by the Tork algorithm, and the automatic identification of topological and three-dimensional molecular symmetries. The modular code base of VeraChem’s software packages allows for flexibility and adaptability in meeting diverse research needs, ensuring that users can leverage these tools effectively for their specific applications.

InSilicoTrials.com is an online platform that offers a user-friendly environment for computational modeling and simulation, featuring a range of integrated, easy-to-navigate in silico tools. It primarily serves professionals in the medical device and pharmaceutical industries. The in silico tools designed for medical devices facilitate computational testing across various biomedical fields, including radiology, orthopedics, and cardiovascular health, during the stages of product design, development, and validation. For the pharmaceutical industry, the platform grants access to in silico tools that support all phases of drug discovery and development across diverse therapeutic areas. We have developed a unique cloud-based platform grounded in crowdscience principles, allowing users to efficiently utilize validated models and reduce their R&D expenses. Additionally, users can explore a continuously expanding catalog of models available for use on a pay-per-use basis, ensuring flexibility and accessibility for their research needs.

To meet ICH M7 guidelines, predict genotoxic and carcinogenic endpoints for impurities and degradations. Impurity profiling Suite is a tool that can be used in your ICH M7 workflow to help you prepare regulatory submissions and stay compliant.

Software to Streamline High-Throughput Experiments From Design to Decide.

The Kanteron Platform assimilated a wide array of medical images, digital pathology slides, genomic sequences, and patient information from various modalities, scanners, sequencers, and databases, delivering a comprehensive data toolkit to all teams within hospital networks. It emphasizes pharmacogenomics to avert adverse medication events and facilitates the application of precision medicine at the point of care by integrating data sources on drug-gene interactions that were formerly only accessible in less user-friendly formats, such as tables found in PDF documents. By incorporating major pharmacogenomic databases like PharmGKB, CGI, DGIdb, and OpenTargets, it enables users to customize their queries according to specific gene families, types of interactions, and drug classifications. Additionally, its adaptable AI allows users to select the dataset that best aligns with their specific use case, applying it effectively to pertinent medical images. This robust functionality not only enhances the accuracy of medical insights but also fosters a more personalized approach to patient care.

Leverage the capabilities of biomedical data through the Polly Platform, which is designed to enhance the scalability of batch jobs, workflows, coding environments, and visualization tools. By facilitating resource pooling, Polly optimally allocates resources according to your specific usage needs and leverages spot instances whenever feasible. This functionality contributes to increased optimization, improved efficiency, quicker response times, and reduced costs associated with resource utilization. Additionally, Polly provides a real-time dashboard for monitoring resource consumption and expenses, effectively reducing the burden of resource management on your IT department. An essential aspect of Polly's framework is its commitment to version control, ensuring that your workflows and analyses maintain consistency through a strategic combination of dockers and interactive notebooks. Furthermore, we've implemented a system that enables seamless co-existence of data, code, and the computing environment, enhancing collaboration and reproducibility. With cloud-based data storage and project sharing capabilities, Polly guarantees that every analysis you conduct can be reliably reproduced and verified. Thus, Polly not only optimizes your workflow but also fosters a collaborative environment for continuous improvement and innovation.

LiveDesign serves as an integrated informatics solution that empowers teams to accelerate their drug discovery initiatives through collaborative design, experimentation, analysis, tracking, and reporting on a unified platform. It allows for the collection of innovative ideas alongside experimental and modeling data seamlessly. Users can develop and archive new virtual compounds within a centralized repository, assess them with sophisticated models, and prioritize the most promising designs. By merging biological data and model outputs from various corporate databases, the platform leverages advanced cheminformatics to provide a comprehensive analysis of all information simultaneously, facilitating quicker compound development. The platform employs cutting-edge physics-based methodologies along with machine learning to enhance prediction accuracy significantly. Teams can collaborate in real-time, regardless of location, enabling them to share concepts, conduct tests, make revisions, and progress chemical series while maintaining a clear record of their work. This not only fosters innovation but also ensures that projects remain organized and efficient throughout the drug discovery process.

Preclinical information is found in many laboratories. It can be stored in multiple systems within the laboratory and with several external partners. Team members are unable to have clear and informed decisions without a unified solution because they lack transparency in core business data. Pristima, a fully integrated digital laboratory execution platform, features intelligent workflows, task automation, and data and information management throughout the entire preclinical process. Xybion's preclinical platform provides a central data repository as well as a standard archive platform. This platform can help you increase productivity and lower costs. With complete transparency across all platforms, gain visibility into the information that is there and take actions based on your current business needs. Effective data management can reduce the time it takes to submit final SENDs from end-of-study.

Experience seamless collaboration and knowledge sharing across your organization with a comprehensive platform that integrates all essential tools, allowing for secure workflows and the use of Phoenix-based applications alongside third-party software. With more than 6,000 researchers relying on Phoenix WinNonlin for non-compartmental analysis (NCA), toxicokinetic modeling, and pharmacokinetic and pharmacodynamic (PK/PD) modeling, it has become the preferred choice among biopharmaceutical companies, academic institutions, and 11 international regulatory bodies, including the US FDA, EMA, and PMDA. Additionally, the Phoenix Platform offers advanced features like population PK/PD (popPK) modeling through Phoenix NLME and Level A correlation capabilities provided by the Phoenix IVIVC Toolkit, while its Validation Suites enable rapid software validation in less than half an hour, ensuring efficiency and compliance. This powerful suite not only enhances research productivity but also fosters innovation by enabling users to streamline their workflows effectively.

LigPlot+ serves as the advanced iteration of the original LIGPLOT software, designed for the automatic creation of 2D diagrams depicting ligand-protein interactions. This tool features a user-friendly Java interface that enables users to edit plots effortlessly through simple mouse click-and-drag actions. Besides the improved interface, LigPlot+ introduces several significant upgrades compared to its predecessor. When analyzing two or more ligand-protein complexes that share notable similarities, the software can automatically present their interaction diagrams either overlayed or side by side, with conserved interactions prominently highlighted for easy identification. Additionally, the LigPlot+ suite integrates an enhanced version of the original DIMPLOT program, which is focused on visualizing protein-protein or domain-domain interactions. Users have the flexibility to choose the specific interface they are interested in, allowing DIMPLOT to produce a detailed diagram that illustrates the residue-residue interactions within that interface. For further clarity in interpretation, the residues from one interface can also be displayed in their sequential order, enhancing the overall usability and functionality of the program. This comprehensive approach makes LigPlot+ a valuable tool for researchers seeking to understand complex molecular interactions more intuitively.

Uncover biological markers, generate insights into the mechanisms of disease, identify novel pharmaceuticals, or detect variations in protein concentrations through a meticulously structured series of experiments. We have simplified the process of harnessing the potential of mass spectrometry and proteomics, enabling you to concentrate on the intricacies of biology and advance toward groundbreaking discoveries. Our automated and consistent workflow facilitates faster initiation and completion of experiments, granting you the authority and adaptability to make timely decisions. By prioritizing biological insights and fostering collaborative efforts, our scalable proteomics data processing system is designed for repeated use. We have delegated intensive and repetitive tasks to the cloud, ensuring a smooth and satisfying experience. Our sophisticated proteomics workflow effectively integrates numerous complex elements, allowing for the efficient analysis and processing of larger-scale experiments, ultimately enhancing the research journey. Thus, with our innovative approach, researchers can now delve deeper into the molecular landscape and achieve more significant breakthroughs than ever before.

DNAnexus Apollo™ enhances the efficiency of precision drug discovery by fostering collaboration that extracts valuable insights from omics data. The process of precision drug discovery involves the aggregation and examination of vast amounts of omics and clinical information. These extensive datasets serve as valuable assets; however, many traditional and custom-built informatics tools struggle to manage their intricacies and scale. Additionally, the effectiveness of precision medicine initiatives can be hindered by fragmented data sources, inadequate collaboration tools, and the challenges posed by complex, evolving regulatory and security demands. By enabling scientists and clinicians to jointly investigate and interpret omics and clinical data within a unified framework, DNAnexus Apollo™ bolsters precision drug discovery efforts. This platform, which is powered by a resilient and scalable cloud infrastructure, facilitates the seamless and secure sharing of data, tools, and analyses among peers and collaborators, regardless of whether they are nearby or across the globe. Ultimately, Apollo not only streamlines the data-sharing process but also enhances the overall collaborative experience in the pursuit of innovative drug discoveries.

At Metabolon, we proudly provide the most extensive Level 1 library in the metabolomics field. Our unique library has been meticulously developed and refined over two decades, boasting more than 5,400 entries. The majority of these entries are classified as Level 1, comprising roughly 85% (around 4,600 entries); however, about 15% of the library consists of Level 2 entries (approximately 800 entries), which are categorized as such due to the unavailability of commercial standards necessary for Level 1 classification. Thanks to our unparalleled library size and exceptional annotation confidence, Metabolon offers precise and highly actionable insights tailored to our clients’ scientific or clinical needs. The applications of metabolomics span a broad spectrum of research areas, including soil health, nutritional studies, preclinical investigations, and clinical trials. Whether you're identifying trends within a population or fine-tuning an individual's treatment plan, metabolomics serves as a powerful tool to uncover crucial answers to pressing questions in various fields. With such extensive resources at your disposal, the potential for discovery is truly limitless.